Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1430070

Minimal Residual Disease Detection in Lymphoma: Methods, Procedures and Clinical significance

Provisionally accepted
Sijun Zhang Sijun Zhang 1Xiangyu Wang Xiangyu Wang 2Zhenzhen Yang Zhenzhen Yang 1Mengjie Ding Mengjie Ding 1Mingzhi Zhang Mingzhi Zhang 1Ken Young Ken Young 3*Xudong Zhang Xudong Zhang 1*
  • 1 First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
  • 2 Beijing Chao-Yang Hospital, Beijing, China
  • 3 Duke University Medical Center, Duke University, Durham, North Carolina, United States

The final, formatted version of the article will be published soon.

    Lymphoma is highly heterogeneous lymphohematopoietic tumor. As our understanding of the biological and pathological characteristics of lymphoma improves, we are identifying an increasing number of lymphoma subtypes.Genotyping has enhanced our ability to diagnose, treat, and monitor the prognosis of lymphoma. Despite significant improvements in treatment effectiveness, traditional methods for assessing disease response and monitoring prognosis are imperfect, and there is no significant improvement in overall remission rates for lymphoma patients.Minimal Residual Disease (MRD) is often indicative of refractory disease or early relapse. For lymphoma patients, personalized MRD monitoring techniques offer an efficient means to estimate disease remission levels, predict early relapse risk, and assess the effectiveness of new drug regimens. In this review, we delve into the MRD procedures in lymphoma, including sample selection and requirements, detection methods and their limitations and advantages, result interpretation. Besides, we also introduce the clinical applications of MRD detection in lymphoma.

    Keywords: Lymphoma, Minimal Residual Disease, liquid biopsy, circulating tumor DNA, Minimal residual disease monitoring

    Received: 09 May 2024; Accepted: 22 Jul 2024.

    Copyright: © 2024 Zhang, Wang, Yang, Ding, Zhang, Young and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ken Young, Duke University Medical Center, Duke University, Durham, 27710, North Carolina, United States
    Xudong Zhang, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.